CD4 and cancer: Compared with IL-2 as antitumor preparations in clinic, CD4+ T cell-derived EVs will not stimulate Tregs, which may suggest a promising new avenue for cancer immunotherapy by fostering a CD8+ T cell-mediated antitumor response (105).